• Species Reactivity
  Mouse
• Specificity
  Detects recombinant mouse Nanog in Western blots. In this format, approximately 50% cross-reactivity with recombinant human Nanog is observed.
• Source
  Polyclonal Goat IgG
• Purification
  Antigen Affinity-purified
• Immunogen
  E. coli-derived recombinant mouse Nanog
  Trp154-Leu262
  Accession # Q80Z64
• Formulation
  Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
• Label
  Unconjugated

• Western Blot
  Yang, W. et al. (2014) Nat. Comm. 5:3818
• CyTOF-ready
  Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
• Immunocytochemistry
  5-15 µg/mL
  See below
• Intracellular Staining by Flow Cytometry
  0.25 µg/10⁶ cells
  See below

• Reconstitution
  Reconstitute at 0.2 mg/mL in sterile PBS.
• Shipping
  The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
• Stability & Storage
  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

• References:
  1. Mitsui, K. et al. (2003) Cell 11:631.
  2. Chambers, I. et al. (2003) Cell 113:643.
  3. Hart, A.H. et al. (2004) Dev. Dyn. 230:187.
• Long Name:
  Nanog Homeobox
• Entrez Gene IDs:
  79923 (Human); 71950 (Mouse)
• Alternate Names:
  FLJ12581; FLJ40451; hNanog; homeobox protein NANOG; Homeobox transcription factor Nanog; homeobox transcription factor Nanog-delta 48; Nanog homeobox; Nanog

Background:

Nanog is a member of the homeobox family of DNA binding transcription factors that has been shown to maintain pluripotency of embryonic stem cells. Its expression is high in undifferentiated embryonic stem cells and is down-regulated during embryonic stem cell differentiation, concomitant with loss of pluripotency
(1-3).       R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。  1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。  天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。  2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。